Management of Positive Anti-Ro/SS-A 52kD Antibody

Clinical Significance and Initial Evaluation

In pregnant women, anti-Ro/SS-A antibodies are associated with risk of neonatal lupus erythematosus and congenital heart block, according to the American College of Rheumatology 1, 2
A comprehensive autoimmune serological panel, including anti-nuclear antibody (ANA) and anti-dsDNA antibody, is recommended for initial evaluation, as suggested by the European League Against Rheumatism 3
Assessing for clinical manifestations of Sjögren's syndrome, such as dry eyes and dry mouth, is crucial in patients with positive anti-Ro/SS-A 52kD antibody, as recommended by the American College of Rheumatology 4
Screening for signs of interstitial lung disease with pulmonary function tests and HRCT is essential in high-risk patients, according to the American Thoracic Society 6

Regular monitoring with clinical assessments every 6-12 months is recommended for asymptomatic patients with isolated anti-Ro/SS-A 52kD positivity, as suggested by the European League Against Rheumatism 3
Symptomatic treatment for sicca symptoms, including artificial tears and saliva substitutes, is recommended for patients with Sjögren's syndrome, according to the American College of Rheumatology 4, 5
Women with anti-Ro/SS-A antibodies should receive serial fetal echocardiography and consider treatment with hydroxychloroquine during pregnancy to reduce risk of congenital heart block, as recommended by the American College of Rheumatology 1, 2
Regular pulmonary function tests and HRCT evaluation are recommended for patients with evidence of interstitial lung disease, according to the American Thoracic Society 6